Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
MELOXICAM
Crookes Healthcare Ltd
15 Milligram
Tablets
2006-07-24
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PA0043/043/002 Case No: 2019779 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to CROOKES HEALTHCARE LTD 1 THANE ROAD WEST, NOTTINGHAM, NG2 3AA, UNITED KINGDOM an authorisation, subject to the provisions of the said Regulations, in respect of the product GALOXIWAY 15 MG TABLETS The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 20/02/2008 until 23/07/2011. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 06/03/2008_ _CRN 2019779_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Galoxiway 15 mg Tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains meloxicam 15 mg. Excipient: this product contains 86mg lactose per tablet For a full list of excipients see section 6.1 3 PHARMACEUTICAL FORM Tablet Pale yellow coloured round tablet with a score line on one side. The tablet can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Short-term symptomatic treatment of exacerbations of osteoarthrosis. Long-term symptomatic treatment of rheumatoid arthritis or ankylosing spondylitis 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Oral use Exacerbations of Read the complete document